Mosunetuzumab + Polatuzumab Vedotin Outperforms R‑GemOx in Transplant‑Ineligible Relapsed/Refractory Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Posted inHematology-Oncology news Oncology

Mosunetuzumab + Polatuzumab Vedotin Outperforms R‑GemOx in Transplant‑Ineligible Relapsed/Refractory Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

In the randomized phase III SUNMO trial, mosunetuzumab plus polatuzumab vedotin significantly improved response rates and progression‑free survival versus R‑GemOx in transplant‑ineligible relapsed/refractory large B‑cell lymphoma, with low rates of clinically significant cytokine release syndrome and improved patient‑reported outcomes.
Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up
Posted inClinical Updates Hematology-Oncology news Specialties

Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up

The 3-year follow-up of the phase III TRANSFORM study demonstrates that lisocabtagene maraleucel (liso-cel) provides superior durable efficacy and a favorable safety profile compared with standard of care in second-line relapsed/refractory large B-cell lymphoma.
Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up
Posted inHematology-Oncology Specialties

Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up

Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell lymphoma with a favorable safety profile.
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
Posted inClinical Updates Hematology-Oncology news Specialties

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study

This phase II trial shows that combining glofitamab with R-CHOP or Pola-R-CHP is safe and effective as first-line treatment in younger patients with high-risk large B-cell lymphoma, achieving high durable response rates and manageable side effects.